Latest news
Debiopharm and Ascepion Pharmaceuticals, Inc. announce an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor,…
Debiopharm Presented Results at the ASCO 2012 Annual meeting – Results of Phase I study with Debio 0932, an oral…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease
The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and…
Debiopharm Group™ presents the ‘Debiopharm Group™ Life Sciences Award 2011’ and two ‘Junior Debiopharm Group™ Awards 2011’ at the ISREC…
Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.